Inovio Pharmaceuticals (NASDAQ:INO) Stock Price Passes Above 200-Day Moving Average - Should You Sell?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.95 and traded as high as $2.25. Inovio Pharmaceuticals shares last traded at $2.14, with a volume of 1,814,162 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on INO shares. HC Wainwright reiterated a "neutral" rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. Oppenheimer decreased their price objective on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating for the company in a research report on Wednesday, May 14th. Wall Street Zen raised shares of Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday, June 27th. Finally, Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $5.00 price target on shares of Inovio Pharmaceuticals in a report on Wednesday, May 14th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $9.75.

Inovio Pharmaceuticals Stock Up 4.9%

The company has a market capitalization of $78.47 million, a PE ratio of -0.67 and a beta of 1.31. The firm has a 50-day moving average of $2.01 and a two-hundred day moving average of $1.95.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.23. The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.01 million. Equities analysts predict that Inovio Pharmaceuticals, Inc. will post -4.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in shares of Inovio Pharmaceuticals by 1,035.2% during the 4th quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company's stock worth $1,173,000 after acquiring an additional 584,521 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in Inovio Pharmaceuticals in the 4th quarter worth about $1,922,000. Bank of Montreal Can purchased a new position in Inovio Pharmaceuticals during the fourth quarter worth approximately $43,000. Jane Street Group LLC grew its holdings in Inovio Pharmaceuticals by 118.2% in the fourth quarter. Jane Street Group LLC now owns 39,704 shares of the biopharmaceutical company's stock valued at $73,000 after purchasing an additional 21,512 shares during the period. Finally, Northern Trust Corp grew its holdings in Inovio Pharmaceuticals by 6.4% in the fourth quarter. Northern Trust Corp now owns 219,057 shares of the biopharmaceutical company's stock valued at $401,000 after purchasing an additional 13,269 shares during the period. Hedge funds and other institutional investors own 26.79% of the company's stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.